Bretylate en es it fr

Bretylate Brand names, Bretylate Analogs

Bretylate Brand Names Mixture

  • No information avaliable

Bretylate Chemical_Formula


Bretylate RX_link

Bretylate fda sheet

Bretylate msds (material safety sheet)

Bretylate MSDS

Bretylate Synthesis Reference

No information avaliable

Bretylate Molecular Weight

243.163 g/mol

Bretylate Melting Point

No information avaliable

Bretylate H2O Solubility

Freely soluble

Bretylate State


Bretylate LogP

No information avaliable

Bretylate Dosage Forms

Solution for injection (50mg/mL)

Bretylate Indication

For use in the prophylaxis and therapy of ventricular fibrillation. Also used in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia, that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine.

Bretylate Pharmacology

Bretylium is a bromobenzyl quaternary ammonium compound which selectively accumulates in sympathetic ganglia and their postganglionic adrenergic neurons where it inhibits norepinephrine release by depressing adrenergic nerve terminal excitability. Bretylium also suppresses ventricular fibrillation and ventricular arrhythmias.

Bretylate Absorption

No information avaliable

Bretylate side effects and Toxicity

Oral, mouse: LD50 = 400 mg/kg. In the presence of life-threatening arrhythmias, underdosing with bretylium probably presents a greater risk to the patient than potential overdosage. However, one case of accidental overdose has been reported in which a rapidly injected intravenous bolus of 30 mg/kg was given instead of an intended 10 mg/kg dose during an episode of ventricular tachycardia. Marked hypertension resulted, followed by protracted refractory hypotension. The patient expired 18 hours later in asystole, complicated by renal failure and aspiration pneumonitis. Bretylium serum levels were 8000 ng/mL.

Bretylate Patient Information

Bretylate Organisms Affected

Humans and other mammals